Team:Imperial College London/Project Overview
From 2009.igem.org
(→Project Overview) |
(→The Problem) |
||
(188 intermediate revisions not shown) | |||
Line 1: | Line 1: | ||
{{Imperial/09/TemplateTop}} | {{Imperial/09/TemplateTop}} | ||
- | + | <!-- | |
+ | Please delete as completed.<br> | ||
+ | Project Overview feedback from todays session:<br> | ||
- | The inspiration behind <i>The E.ncapsulator</i> was the inherent difficulty in delivering protein pharmaceuticals to the gut. Due to the delicate nature of proteins and the highly acidic environment present in the stomach, protein molecules are readily broken down - making oral drug delivery of protein pharmaceuticals | + | 1) Bold important sentences/words<br> |
+ | 2) Why are we giving stats on Turkey? Stick to the European union, large well known places! Add references - from the registry page.<br> | ||
+ | 3) Manufacturing considerations - why is this below our solution? Should we make it more like specs? Would this link better?<br> | ||
+ | 4) Results - If no data exists - say that as the wiki is being frozen we haven't added the data but will have it in time for the Jamboree.<br> | ||
+ | 5) Have a conclusion of the page at the end - couple of lines.<br> | ||
+ | 6) Remove !'s in learn mores<br> | ||
+ | 7) Write this, then we will decide the order.<br> | ||
+ | --> | ||
+ | |||
+ | =The Problem= | ||
+ | <!--[[Image:II09_Theproblem2.png|220px|right]]--> | ||
+ | The inspiration behind <b><i>The E.ncapsulator</i></b> was the inherent difficulty in delivering protein pharmaceuticals to the gut. Due to the delicate nature of proteins and the highly acidic environment present in the stomach, <b>protein molecules are readily broken down - making oral drug delivery of protein pharmaceuticals very difficult </b>.<br> | ||
+ | |||
+ | There are several diseases that are treated using oral delivery of peptides. Among these are: | ||
+ | <b>Malnutrition (world hunger)</b> and <b>Phenylketonuria (PKU)</b>, a disease associated with mental retardation due to insufficient ability to metabolise phenylalanine.<br> | ||
+ | |||
+ | [[Image:II09_enzyme.png|right|200px]] | ||
+ | In this project, we chose several different potential applications to illustrate the versatility of <b><i>The E.ncapsulator</i></b>. Firstly, we chose to synthesise phenylalanine hydroxylase (PAH), an enzyme responsible for metabolism of phenylalanine - and an enzyme that is deficient in PKU patients. Secondly we chose to synthesise the enzyme cellulase, in order to derive better nutritional value from food consumed to aleviate malnutrition around the world. Finally we chose to synthesise a small bioactive pentapeptide, opiorphin. This small molecule acts very efficiently as a pain killer and anti-depressant, whilst due to its mechanism of action, remaining non-addictive. <br><br><b><i>The E.ncapsulator</i> system is a generic drug production and delivery platform. The project great offers potential for any problem that requires the delivery of polypeptide biopharmaceuticals to the lower GI tract.</b> | ||
+ | |||
+ | ==Some statistics== | ||
+ | In the table below we have provided some statistics of disorders requiring administration of polypeptide drugs. This highlights the need for a <b>cost-effective and implementable solution, which is what we is offered by <i>The E.ncapsulator</i>.</b> | ||
+ | <!--template:----------------------------------------------------------------------------> | ||
+ | {| style="color:#CCC; background-color:#325d97;" cellpadding="6" cellspacing="0" border="3" | ||
+ | ! Malnutrition (from [3]) | ||
+ | ! PKU (from [4-5]) | ||
+ | |- style="color:#333; background-color:#CCCCFF;" cellpadding="6" cellspacing="0" border="1" | ||
+ | <!----------------------------------------biobricks----------------------------------------> | ||
+ | | 854 million people worldwide are suffering from malnutrition (12.6% of the world population) | ||
+ | | 1 per 10,000 - 15,000 newborns are diagnosed with phenylketonuria in the USA | ||
+ | |- style="color:#333; background-color:#CCCCFF;" cellpadding="6" cellspacing="0" border="1" | ||
+ | | 820 million in developing countries | ||
+ | | It occurs with a frequency of between 1 in 4.500 (Turkey and Ireland) and 1 in 10.000 in most of Europe although in Finland the frequency is lower at 1 in 40.000 new born babies. | ||
+ | |} | ||
+ | <!-- | ||
+ | *PKU (statistics from [1]): | ||
+ | ** 1 per 10,000 - 15,000 newborns are diagnosed with phenylketonuria in the USA | ||
+ | ** Prevalance Rate: approx 1 in 10,000 or 0.01% or 27,200 people in USA | ||
+ | *Diabetes Mellitus (statistics from [2]): | ||
+ | **17,000,000 U.S. adults have physician-diagnosed diabetes (about 7.5 million males and 9.5 million females). | ||
+ | **1,600,000 new cases of diagnosed diabetes are diagnosed every year. | ||
+ | --> | ||
+ | |||
+ | <!-- NOTES FOR THIS PAGE | ||
+ | Prevalance of Phenylketonuria: 1 per 10,000 - 15,000 newborns are diagnosed with phenylketonuria in the US, Genetics Home Reference website | ||
+ | Prevalance Rate: approx 1 in 10,000 or 0.01% or 27,200 people in USA [about data] | ||
+ | Incidence (annual) of Phenylketonuria: 1 of every 10,000 infants in the United States (NIDCD) | ||
+ | Incidence Rate: approx 1 in 10,000 or 0.01% or 27,200 people in USA [about data] | ||
+ | Incidence extrapolations for USA for Phenylketonuria: 27,199 per year, 2,266 per month, 523 per week, 74 per day, 3 per hour, 0 per minute, 0 per second. Note: this extrapolation calculation uses the incidence statistic: 1 of every 10,000 infants in the United States (NIDCD) | ||
+ | |||
+ | http://www.wrongdiagnosis.com/p/phenylketonuria/stats.htm | ||
+ | |||
+ | 17,000,000 U.S. adults have physician-diagnosed diabetes (about 7.5 million males and 9.5 million females). | ||
+ | 1,600,000 new cases of diagnosed diabetes are diagnosed every year. | ||
+ | 2005 death rates were 26.5 per 100,000 white males, 50.8 per 100,000 black males; 19.3 per 100,000 white females and 43.8 per 100,000 black females. | ||
+ | 584,000 people diagnosed with diabetes mellitus were discharged from U.S. hospitals in 2006. Of these, 283,000 were males and 301,000 were females. | ||
+ | At least 65 percent of people with diabetes mellitus die of some form of heart disease or stroke. | ||
+ | The age-adjusted (2000 standard) prevalence of physician-diagnosed diabetes in adults age 20 and older is (NHANES [2003–06], NCHS/NHLBI)... | ||
+ | |||
+ | For non-Hispanic whites, 5.8 percent of men and 6.1 percent of women. | ||
+ | For non-Hispanic blacks, 14.9 percent of men and 13.1 percent of women. | ||
+ | For Mexican Americans, 11.3 percent of men and 14.2 percent of women. | ||
+ | The percentage of adults age 18 and older who have been told they have diabetes is 17.2 percent of American Indians/Alaska Natives; 8.9 percent of Asians and 11.1 percent of Hispanics or Latinos (NHIS [2007], NCHS). | ||
+ | |||
+ | http://www.americanheart.org/presenter.jhtml?identifier=4551 | ||
+ | --> | ||
+ | |||
+ | ==Project specifications== | ||
+ | *<b>Synthesis:</b> The system is generic and potentially able to manufacture any type of polypeptide. | ||
+ | *<b>Purification:</b> In <i><b>The E.ncapsulator</b></i>, protein production (module 1) and encapsulation (module 2) of the cells occur in the same place. This dual production and delivery platform means that there is no need for expensive downstream purification processes. | ||
+ | *<b>Storage:</b> Freeze drying in the encapsulation phase and secondary encapsulation allow for storage of <b><i>The E.ncapsulator</i></b>. | ||
+ | *<b>Quality Control:</b> If one cell fails to produce the protein or polypeptide of interest, it will have minimal impact on the whole system. | ||
+ | *<b>Safety:</b> In order to reduce risks associated with our product, we have chosen a GRAS (generally recognised as safe) chassis. Furthermore, all the genetic material is destroyed prior ingestion to prevent any risks of horizontal gene transfer after colonisation by the cell. | ||
+ | |||
+ | =Our Solution= | ||
+ | <b><i>The E.ncapsulator</i></b> is a novel protein manufacture and delivery platform designed to overcome these difficulties. Hover over the different parts of the image below, to learn more about each module of the system: | ||
+ | <br> | ||
+ | {{Imperial/09/Overview}} | ||
+ | |||
+ | <!--=Motivation= | ||
+ | NP. INCLUDE STUFF FROM SLIDES. DISCUSS JAMES AND DINEKA. WE NEED TO SAY WHY WE'RE DOING WHAT WE'RE DOING. | ||
+ | ALSO, STATS ETC | ||
+ | --> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | <!--=Motivation= | ||
+ | NP. INCLUDE STUFF FROM SLIDES. DISCUSS JAMES AND DINEKA. WE NEED TO SAY WHY WE'RE DOING WHAT WE'RE DOING. | ||
+ | ALSO, STATS ETC | ||
+ | --> | ||
+ | <!-- | ||
+ | =Major Results= | ||
+ | ==Simulations: Chemoinduction/Module 1-Output yield of drug of interest== | ||
+ | Our simulation results indicate that increasing input amounts of IPTG result in a greater yield of polypeptide drug of interest, provided that input concentrations are not within a toxic range. For more information see our [https://2009.igem.org/Team:Imperial_College_London/Drylab/Protein_Production simulation results] and [https://2009.igem.org/Team:Imperial_College_London/Wetlab/Results/Cheminduction/IPTG experimental results on toxicity]. <br> | ||
+ | [[Image:II09_SIm_main_prot.jpg]]<br> | ||
+ | Note: Parameters are arbitrary. For a justification see [https://static.igem.org/mediawiki/2009/a/a0/II09_Prot_stability_analysis.pdf the system stability analysis.] | ||
+ | |||
+ | ==Experimental: Module 2 - Encapsulation growth curves== | ||
+ | Dependent on lab results today | ||
+ | |||
+ | ==Experimental: Autoinduction - Diauxic growth curve and CRP GFP== | ||
+ | Here we can pick a diauxic growth curve and compare directly to a simulation (if I manage to make one work!! :-S) | ||
+ | |||
+ | ==Simulations: Module 1 - Enzyme kinetics and dosage control== | ||
+ | [[Image:II09_enzymekinetics.png|330px|left]]<br> | ||
+ | Many polypeptides of interest are enzymes. This means that detecting how much drug has been produced requires knowledge about their interaction with their respective substrates in the enzymatic assays. Here we assumed that enzymatic activity follows Michaelis-Menten kinetics [7]. This means that we can directly relate enzymatic activity to the required dosage for successful administration of the polypeptide of interest. <br> | ||
+ | <b>Dosage Calculations:</b><br> | ||
+ | Tianyi upload once we work out activity or whatever is necessary!<br><br><br><br> | ||
+ | |||
+ | ==Experimental: Module 3 - Thermoinducible promoter== | ||
+ | Need Matthieu's latest processed data | ||
+ | |||
+ | =Conclusion= | ||
+ | Need some inspiration here guys! | ||
+ | --> | ||
+ | |||
+ | <!-- | ||
<html> | <html> | ||
<center> | <center> | ||
<div class="highslide-gallery"> | <div class="highslide-gallery"> | ||
- | <a href=" | + | <a href="http://i691.photobucket.com/albums/vv271/dk806/MainOverviewPicPO-1.jpg" class="highslide" onclick="return hs.expand(this)"> |
- | <img src=" | + | <img src="http://i691.photobucket.com/albums/vv271/dk806/MainOverviewPicPO-1.jpg" alt="" title="Click to enlarge"/> |
</a> | </a> | ||
<div class="highslide-caption"> | <div class="highslide-caption"> | ||
Line 16: | Line 134: | ||
</center> | </center> | ||
</html> | </html> | ||
- | + | --> | |
- | Modularity is key to the design of <i>The E.ncapsulator</i>. In order to simplify the system, and to increase reusability, the system has been divided into 3 active modules. These are as follows:<br> | + | <!-- |
+ | Modularity is key to the design of <b><i>The E.ncapsulator</i></b>. In order to simplify the system, and to increase reusability, the system has been divided into 3 active modules. These are as follows:<br> | ||
#<b>[[Team:Imperial_College_London/M1 |Module 1]]: Protein Production</b> | #<b>[[Team:Imperial_College_London/M1 |Module 1]]: Protein Production</b> | ||
#*The first module involves engineering <i>E.coli</i> to synthesise the protein drug of interest to sufficient quantities.<br> | #*The first module involves engineering <i>E.coli</i> to synthesise the protein drug of interest to sufficient quantities.<br> | ||
#<b>[[Team:Imperial_College_London/M2 |Module 2]]: Encapsulation</b> | #<b>[[Team:Imperial_College_London/M2 |Module 2]]: Encapsulation</b> | ||
- | #* <i>E.coli</i> coats itself in a protective layer of colanic acid to form | + | #* <i>E.coli</i> coats itself in a protective layer of colanic acid to form <b><i>The E.ncapsulator</i></b>. This protective capsule is what protects the biopharmaceutical against the harsh acidic environment of the stomach. This module also codes for the production of a protective sugar, trehalose, which will protect the protein of interest under storage conditions, and will allow for freeze drying.<br> |
#<b>[[Team:Imperial_College_London/M3 |Module 3]]: Genome Deletion</b> | #<b>[[Team:Imperial_College_London/M3 |Module 3]]: Genome Deletion</b> | ||
#*The third module, genome deletion, is composed of a ‘suicide trigger’ mechanism that destroys the genetic material of the bacteria, leaving the cell membrane left intact. This killing strategy means the biopharmaceutical remains protected even after the cell is dead.<br> | #*The third module, genome deletion, is composed of a ‘suicide trigger’ mechanism that destroys the genetic material of the bacteria, leaving the cell membrane left intact. This killing strategy means the biopharmaceutical remains protected even after the cell is dead.<br> | ||
Line 29: | Line 148: | ||
In order to demonstrate the feasability of <i>The E.ncapsulator</i> as a new drug delivery platform, we have chosen to program the system to manufacture 2 enzyme pharmaceuticals, cellulase and PAH.<br><br><br> | In order to demonstrate the feasability of <i>The E.ncapsulator</i> as a new drug delivery platform, we have chosen to program the system to manufacture 2 enzyme pharmaceuticals, cellulase and PAH.<br><br><br> | ||
+ | --> | ||
- | <html>< | + | ==References== |
- | <a href="https://2009.igem.org/Team:Imperial_College_London"><img width=150px src=" | + | [1] [http://www.americanheart.org/presenter.jhtml?identifier=4551 Diabetes Mellitus statistics]<br> |
- | <a href="https://2009.igem.org/Team:Imperial_College_London/ | + | [2] [http://www.wrongdiagnosis.com/h/hemophilia/stats.htm Hemophilia statistics]<br> |
+ | [3] [http://www.worldhunger.org/articles/Learn/world%20hunger%20facts%202002.htm World Hunger statistics]<br> | ||
+ | [4] [http://www.wrongdiagnosis.com/p/phenylketonuria/stats.htm Phenylketonuria in the USA]<br> | ||
+ | [5] [http://www.espku.org/3.0/index.php?option=com_content&task=view&id=1&Itemid=2 ESPKU (European statistics)]<br> | ||
+ | [6] [http://www.wrongdiagnosis.com/p/phenylketonuria/stats-country.htm More PKU statistics (browse per country)]<br> | ||
+ | [7] [http://www.chm.davidson.edu/erstevens/Michaelis/Michaelis.html Michaelis-Menten kinetics] | ||
+ | <br> | ||
+ | <Center> | ||
+ | ===Project Tour=== | ||
+ | <html> | ||
+ | <Center> | ||
+ | |||
+ | <a href="https://2009.igem.org/Team:Imperial_College_London"><img width=150px src="http://i691.photobucket.com/albums/vv271/dk806/HomeL.jpg"></a> | ||
+ | <a href="https://2009.igem.org/Team:Imperial_College_London/Chemoinduction"><img width=150px src="http://i691.photobucket.com/albums/vv271/dk806/CIR.jpg"></a></center> | ||
</html> | </html> | ||
+ | <br> | ||
- | + | <hr> | |
- | + | <b>These links may be useful to browse our results and achievements: </b></center> | |
<html><center><a href="https://2009.igem.org/Team:Imperial_College_London/Major_results"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage2.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Wetlab/BioBricks"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage3.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Achievements"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage4.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Manufacturing_Considerations"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage5.png"></a><html><a | <html><center><a href="https://2009.igem.org/Team:Imperial_College_London/Major_results"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage2.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Wetlab/BioBricks"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage3.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Achievements"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage4.png"></a><a href="https://2009.igem.org/Team:Imperial_College_London/Manufacturing_Considerations"><img style="vertical-align:bottom;" width="19%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage5.png"></a><html><a | ||
- | href="https://2009.igem.org/Team:Imperial_College_London/genealogy"><img style="vertical-align:bottom;" width="23%" src="https://static.igem.org/mediawiki/2009/2/20/II09_WorldMap.png"></a><center></html> | + | href="https://2009.igem.org/Team:Imperial_College_London/genealogy"><img style="vertical-align:bottom;" width="23%" src="https://static.igem.org/mediawiki/2009/2/20/II09_WorldMap.png"></a><center></center></html> |
<html><table border="0" style="background-color:transparent;" width="100%"> | <html><table border="0" style="background-color:transparent;" width="100%"> | ||
Line 51: | Line 185: | ||
<td width="20%"><center><a href="https://2009.igem.org/Team:Imperial_College_London/genealogy"><b>Genealogy</b></a></center></td> | <td width="20%"><center><a href="https://2009.igem.org/Team:Imperial_College_London/genealogy"><b>Genealogy</b></a></center></td> | ||
<td width="20%"><center><b> </b></a></center></td> | <td width="20%"><center><b> </b></a></center></td> | ||
- | |||
</tr></table></html> | </tr></table></html> | ||
+ | |||
+ | <html> | ||
+ | </center> | ||
+ | </html> | ||
+ | <br><br><br> | ||
{{Imperial/09/TemplateBottom}} | {{Imperial/09/TemplateBottom}} |
Latest revision as of 01:20, 22 October 2009
Contents |
The Problem
The inspiration behind The E.ncapsulator was the inherent difficulty in delivering protein pharmaceuticals to the gut. Due to the delicate nature of proteins and the highly acidic environment present in the stomach, protein molecules are readily broken down - making oral drug delivery of protein pharmaceuticals very difficult .
There are several diseases that are treated using oral delivery of peptides. Among these are:
Malnutrition (world hunger) and Phenylketonuria (PKU), a disease associated with mental retardation due to insufficient ability to metabolise phenylalanine.
In this project, we chose several different potential applications to illustrate the versatility of The E.ncapsulator. Firstly, we chose to synthesise phenylalanine hydroxylase (PAH), an enzyme responsible for metabolism of phenylalanine - and an enzyme that is deficient in PKU patients. Secondly we chose to synthesise the enzyme cellulase, in order to derive better nutritional value from food consumed to aleviate malnutrition around the world. Finally we chose to synthesise a small bioactive pentapeptide, opiorphin. This small molecule acts very efficiently as a pain killer and anti-depressant, whilst due to its mechanism of action, remaining non-addictive.
The E.ncapsulator system is a generic drug production and delivery platform. The project great offers potential for any problem that requires the delivery of polypeptide biopharmaceuticals to the lower GI tract.
Some statistics
In the table below we have provided some statistics of disorders requiring administration of polypeptide drugs. This highlights the need for a cost-effective and implementable solution, which is what we is offered by The E.ncapsulator.
Malnutrition (from [3]) | PKU (from [4-5]) |
---|---|
854 million people worldwide are suffering from malnutrition (12.6% of the world population) | 1 per 10,000 - 15,000 newborns are diagnosed with phenylketonuria in the USA |
820 million in developing countries | It occurs with a frequency of between 1 in 4.500 (Turkey and Ireland) and 1 in 10.000 in most of Europe although in Finland the frequency is lower at 1 in 40.000 new born babies. |
Project specifications
- Synthesis: The system is generic and potentially able to manufacture any type of polypeptide.
- Purification: In The E.ncapsulator, protein production (module 1) and encapsulation (module 2) of the cells occur in the same place. This dual production and delivery platform means that there is no need for expensive downstream purification processes.
- Storage: Freeze drying in the encapsulation phase and secondary encapsulation allow for storage of The E.ncapsulator.
- Quality Control: If one cell fails to produce the protein or polypeptide of interest, it will have minimal impact on the whole system.
- Safety: In order to reduce risks associated with our product, we have chosen a GRAS (generally recognised as safe) chassis. Furthermore, all the genetic material is destroyed prior ingestion to prevent any risks of horizontal gene transfer after colonisation by the cell.
Our Solution
The E.ncapsulator is a novel protein manufacture and delivery platform designed to overcome these difficulties. Hover over the different parts of the image below, to learn more about each module of the system:
- Growth
-
GrowthThe cells are grown to a critical cell density, before the system is started. It allows the culture to reach a sufficient cell number before the the cells are triggered to begin protein production. This is because protein production can slow cell growth.
- Module 1: Protein Production
-
Module 1: Protein ProductionThe first module is induced with IPTG, which triggers the production of the protein of interest. As part of this project we have looked into two proteins and a peptide of interest.
- Module 2: Encapsulation
-
Module 2: EncapsulationThe second module is where the cell, after having produced the peptide of interest, produces colanic acid. This creates a protecting layer around teh bacterium to shelter it from the acidity of the stomach.
- Module 3: Genome deletion
-
Module 3: Genome deletionModule 3 occurs after encapsulation of the cell containing the produced peptide of interest. This module makes the bacterium non-viable. It does so by over-expressing restriction enzymes which subsequently cleave the genomic DNA into small fragments. The cell is thus unable to produce any proteins and therefore unable to survive.
- Secondary Encapsulation
-
Secondary EncapsulationSeveral manufacturing considerations regarding the post-processing of the culture have been investigated. Post-processing of the culture allows the polypeptide filled cells to be converted into a pharmaceutical tablet, that can be taken orally.
- Chemoinduction
-
Module Integration: ChemoinductionModule 1 is induced by the addition of a compound, IPTG. This allows the user to 'kickstart' the system once the culture has reached a sufficiently high cell density.
- Autoinduction
-
Module Integration: AutoinductionModule 2 is triggered by a switch from glucose consumption to a secondary carbon source consumption. When the initial preferential carbon source (glucose) is exhausted, the system will metabolise the secondary carbon source that is available. This switch triggers the promoter that controls the start of Module 2. By knowing the initial concentrations of each carbon source, this acts as a programmable time delay system for the activation of encapsulation.
- Thermoinduction
-
Module Integration: ThermoinductionModule 3 is initiated upon an increase in temperature. The system is initially grown at 28°C, at which point Module 3 is repressed. When the temperature is raised to 42°C, this repression is blocked, triggering the start of Module 3. This temperature sensitive system was chosen as after encapsulation, chemical induction may be less effective due to limited diffusion.
References
[1] [http://www.americanheart.org/presenter.jhtml?identifier=4551 Diabetes Mellitus statistics]
[2] [http://www.wrongdiagnosis.com/h/hemophilia/stats.htm Hemophilia statistics]
[3] [http://www.worldhunger.org/articles/Learn/world%20hunger%20facts%202002.htm World Hunger statistics]
[4] [http://www.wrongdiagnosis.com/p/phenylketonuria/stats.htm Phenylketonuria in the USA]
[5] [http://www.espku.org/3.0/index.php?option=com_content&task=view&id=1&Itemid=2 ESPKU (European statistics)]
[6] [http://www.wrongdiagnosis.com/p/phenylketonuria/stats-country.htm More PKU statistics (browse per country)]
[7] [http://www.chm.davidson.edu/erstevens/Michaelis/Michaelis.html Michaelis-Menten kinetics]
Project Tour
These links may be useful to browse our results and achievements: